Sempra
$88.05B- Market cap
- $54.94B
- Debt
- +$33.15B
- Cash
- −$29.00M
Capital structure 62% equity / 38% debt · EV / Revenue 6.43x · EV / EBITDA 13.46x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $54.94B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: SRE stock price near parity vs SUPN $84.04 current versus $73.80 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SUPN's multiple
Implied fair value · at SRE's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRE FY 2025 (ended Dec 31, 2025) · SUPN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 62% equity / 38% debt · EV / Revenue 6.43x · EV / EBITDA 13.46x
Capital structure 98% equity / 2% debt · EV / Revenue 3.40x · EV / EBITDA 50.55x
SRE carries the larger enterprise value at $88.05B against $2.45B; SUPN trades on the lower EV / Revenue multiple (3.40x vs 6.43x); SRE on the lower EV / EBITDA (13.46x vs 50.55x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
SEMPRA · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.05x
0.04x
Net debt / EBITDA
Leverage against operating earnings
5.06x
-1.75x
Cash and equivalents
Liquid reserves on the balance sheet
$29.00M
$128.45M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
DOMINION ENERGY, INC
SRE vs D
WILLIAMS COMPANIES, INC.
SRE vs WMB
ATMOS ENERGY CORP
SRE vs ATO
ONE Gas, Inc.
SRE vs OGS
NATIONAL FUEL GAS CO
SRE vs NFG
Jazz Pharmaceuticals plc
SRE vs JAZZ
INCYTE CORP
SRE vs INCY
ANI PHARMACEUTICALS INC
SRE vs ANIP
Vanda Pharmaceuticals Inc.
SRE vs VNDA
Harmony Biosciences Holdings, Inc.
SRE vs HRMY
$33.15B
$43.80M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.